EUROPE CARDIOVASCULAR ULTRASOUND MARKET FORECAST 2026-2034

The growing integration of AI-assisted echocardiography, 3D and 4D imaging, and handheld echocardiography devices across European healthcare systems is further reshaping clinical workflows, improving diagnostic efficiency, and driving equipment refresh cycles across hospitals, diagnostic centers, and ambulatory care centers. These factors, in turn, are set to boost the Europe cardiovascular ultrasound market growth during the forecast period.

The Europe cardiovascular ultrasound market growth assessment includes the analysis of the United Kingdom, Germany, France, Italy, Spain, Belgium, Poland, and Rest of Europe.

The United Kingdom is one of the most significant individual contributors to the European cardiovascular ultrasound market, underpinned by a high and well-documented cardiovascular disease burden alongside a centralized National Health Service (NHS) framework that prioritizes non-invasive cardiac diagnostic procedures. According to NHS England, cardiovascular disease is responsible for one in four premature deaths in the UK, defined as deaths occurring in people under the age of 75.

Research published in The Lancet Public Health analyzing NHS England electronic health records for over 57 million people between 2020 and 2024 found that monthly crude incidence rates for ischemic stroke and myocardial infarction remain substantial, highlighting the ongoing clinical urgency for cardiovascular imaging tools. The UK government’s Major Conditions Strategy, formally includes cardiovascular disease as one of six priority condition groups, signaling a top-down policy commitment to strengthening early detection and cardiovascular care pathways, including expanded access to cardiovascular ultrasound across integrated care boards.

The NHS Long Term Plan’s cardiac transformation program further aims to prevent 150,000 strokes, heart attacks, and dementia cases over a decade, creating a sustained, policy-backed demand environment for cardiac diagnostic procedures. From a vendor strategy standpoint, the UK presents a compelling opportunity for companies offering AI-enabled systems that support remote image reading and automated workflows, particularly given ongoing staffing pressures across NHS cardiology departments.

Germany is the largest economy in Europe and one of the most important markets for advanced cardiovascular imaging, driven by an exceptionally high burden of cardiovascular disease and a well-funded statutory health insurance system that supports broad clinical access to cardiac imaging. According to the German Federal Statistical Office (Destatis), cardiovascular diseases remain the leading cause of death in Germany, accounting for approximately 33.9% of all deaths, with an estimated 340,000 deaths attributed to heart disease annually.

Coronary heart disease is specifically the leading cause of death in Germany, as confirmed by research published in PMC based on data from the Federal Statistical Office. Germany’s statutory health insurance system, known as the GKV (Gesetzliche Krankenversicherung), provides comprehensive reimbursement for echocardiographic procedures, removing a significant financial barrier to cardiac ultrasound adoption and enabling broad access across the country’s dense hospital and outpatient clinic network.

Germany also has the third-oldest population in the world after Monaco and Japan, according to the SHD Coalition, which makes age-related cardiac conditions, including heart failure, valvular disease, and atrial fibrillation, increasingly prevalent drivers of echocardiography demand. The country’s robust R&D ecosystem and strong appetite for premium cardiac imaging systems also make it a key early-adoption market for next-generation cardiovascular ultrasound technologies, including AI-powered and 3D/4D platforms, giving vendors a strategically important foothold in the broader European cardiovascular imaging market.

The Europe cardiovascular ultrasound market is segmented by device display, technology, application, type, and end-user. The technology segment is further categorized into 2D ultrasound, 3D & 4D ultrasound, and Doppler imaging.

Doppler imaging holds a significant share within the technology segment of the Europe cardiovascular ultrasound market, and its clinical and commercial significance in the region is well-established. Doppler imaging enables clinicians to assess the direction, velocity, and pattern of blood flow through cardiac chambers and vessels in real time, capabilities that are indispensable for diagnosing valvular disorders, detecting congenital heart defects, assessing diastolic dysfunction, and monitoring hemodynamic changes across a broad spectrum of cardiovascular diseases.

In Europe, where cardiovascular mortality is exceptionally high and early diagnostic accuracy is a clinical and policy priority, Doppler imaging by modality provides the level of functional cardiac detail that structural 2D imaging alone cannot deliver. Its integration with color flow mapping further enhances its diagnostic versatility, making it the technology of choice across hospital echo labs, diagnostic centers, and ambulatory care centers throughout the region.

The segment also benefits from continuous innovation, as manufacturers increasingly embed AI-assisted flow quantification and automated Doppler measurements into next-generation cardiac ultrasound systems, reducing operator dependency and improving reproducibility across diverse clinical settings. For investors and vendors operating in the European cardiovascular imaging market, the Doppler imaging segment represents both a high-volume demand base and a premium technology upgrade opportunity, particularly as European health systems accelerate their adoption of AI-enhanced echocardiography platforms to address staffing constraints and rising cardiac procedure volumes.

Some of the top players operating in the Europe cardiovascular ultrasound market include Esaote SpA, Koninklijke Philips NV, Siemens Healthineers AG, GE HealthCare, etc.

Esaote SpA is a Genoa, Italy-headquartered medical imaging company and one of Europe’s most strategically relevant players in the cardiovascular ultrasound market. The company specializes in ultrasound systems, dedicated magnetic resonance imaging, and healthcare IT, with a particular focus on cardiovascular diagnostics. Its cardiac ultrasound portfolio spans console-based systems to premium portable units, all equipped with comprehensive cardiac and vascular packages designed for early detection and preventive healthcare.

At the European Society of Cardiology (ESC) Congress 2025 in Madrid, Esaote launched the MyLab™C30 cardio, a portable cardiovascular ultrasound system specifically engineered for cardiology, featuring AI-powered tools and its HeartScan Assistant for real-time transthoracic echocardiogram guidance, reinforcing its commitment to advancing cardiac diagnostic procedures across the European cardiovascular imaging market.